COPD-Journal of Chronic Obstructive Pulmonary Disease
Scope & Guideline
Bridging science and clinical practice for respiratory care.
Introduction
Aims and Scopes
- Clinical Research on COPD Management:
The journal publishes studies on various management strategies for COPD, including pharmacological and non-pharmacological interventions, emphasizing evidence-based practices and outcomes. - Pathophysiology and Molecular Mechanisms:
Research exploring the underlying biological mechanisms of COPD, including genetic, molecular, and cellular studies that contribute to understanding disease progression and potential therapeutic targets. - Epidemiological Studies:
Publications include large-scale epidemiological studies that analyze trends, risk factors, and healthcare utilization related to COPD, providing insights into public health implications. - Patient-Centered Care and Quality of Life:
The focus on patient-reported outcomes and quality of life assessments highlights the importance of understanding the patient's perspective in managing COPD. - Innovative Diagnostics and Technologies:
Research on new diagnostic tools and technologies, including imaging techniques and biomarker discovery, aimed at improving early detection and monitoring of COPD. - Rehabilitation and Self-Management:
Studies on pulmonary rehabilitation programs and self-management strategies that empower patients to manage their condition effectively.
Trending and Emerging
- Integration of Machine Learning in COPD Management:
The use of machine learning and artificial intelligence for diagnosing and predicting COPD outcomes is on the rise, showcasing a shift towards data-driven approaches in clinical practice. - Long-COVID and its Relationship with COPD:
Emerging research examining the intersection of long-COVID and COPD highlights the need for understanding respiratory complications in post-viral syndromes, which is increasingly relevant in the current healthcare landscape. - Focus on Inflammation and Immune Response:
Recent studies are emphasizing the role of inflammation and immune mechanisms in COPD pathogenesis, suggesting new therapeutic avenues that target these processes. - Holistic and Multidisciplinary Approaches:
An increasing number of publications are addressing the psychosocial aspects of COPD, including mental health, social participation, and patient-centered care strategies. - Role of Comorbidities in COPD Outcomes:
Research exploring the impact of comorbid conditions, such as diabetes and cardiovascular diseases, on COPD prognosis is gaining traction, reflecting a more integrated view of patient health.
Declining or Waning
- Traditional Pharmacological Treatments:
Research focused on traditional pharmacological treatments for COPD, such as corticosteroids and bronchodilators, seems to be declining as new therapies and combination treatments gain prominence. - Basic Science Research Unrelated to COPD:
There is a noticeable decrease in studies that explore basic science concepts not directly related to COPD pathophysiology, as the journal shifts towards more applied and clinically relevant research. - Single-Disease Focus Studies:
Publications that exclusively focus on COPD without considering comorbidities or the impact of multimorbidity are less common, reflecting a growing recognition of the complexity of patient profiles in COPD. - Outdated Diagnostic Methods:
Research on older diagnostic approaches that do not incorporate recent advancements in technology and personalized medicine is becoming less frequent, indicating a shift toward more innovative methodologies.
Similar Journals
Multidisciplinary Respiratory Medicine
Fostering breakthroughs in respiratory science for all.Multidisciplinary Respiratory Medicine is a leading open-access journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by MATTIOLI 1885, this journal has been serving the academic community since 2008 and has become a vital platform for the dissemination of research and clinical insights in this critical area of healthcare. With an impressive impact factor placing it in the Q2 category of pulmonary medicine in 2023 and a Scopus rank of #67 out of 155, it reflects a solid commitment to high-quality research. The journal provides researchers, health professionals, and students with accessible and updated information, fostering collaboration and advancement in respiratory health. Operating from the United Kingdom, it has embraced open access since 2010, ensuring that all articles are freely available, thus maximizing the reach and impact of its scholarly contributions. Whether you are looking to publish innovative findings or gain insights from industry leaders, Multidisciplinary Respiratory Medicine is your go-to resource for the latest in respiratory science.
RESPIRATORY MEDICINE
Pioneering Research for Better BreathingRespiratory Medicine is a leading journal in the field of pulmonary and respiratory medicine, dedicated to advancing knowledge and research from 1989 to 2024. Published by W B Saunders Co Ltd, this esteemed journal is recognized for its high impact, reflected in its Q1 quartile ranking in 2023 within the category of Pulmonary and Respiratory Medicine and its impressive Scopus ranking of 27 out of 155 journals, placing it in the 82nd percentile. With a focus on publishing groundbreaking research, comprehensive reviews, and innovative practices, Respiratory Medicine serves as an essential resource for health professionals, researchers, and students aiming to improve patient outcomes and understand complex respiratory conditions. While the journal is not Open Access, its contributions to the scientific community are invaluable, providing insights that drive both academic and clinical advancements in respiratory health.
Tuberkuloz ve Toraks-Tuberculosis and Thorax
Fostering dialogue on thoracic health challenges.Tuberkuloz ve Toraks (Tuberculosis and Thorax) is a distinguished journal published by the TURKISH ASSOCIATION OF TUBERCULOSIS AND THORAX located in Turkey. Serving as a pivotal platform for researchers and practitioners in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, this journal has been disseminating vital research since 2003 and is committed to advancing knowledge and clinical practices related to tuberculosis and thoracic diseases. Although currently not an Open Access publication, its relevance is underscored by its rankings within Scopus, including a Q3 category in Critical Care and Intensive Care Medicine and a Q4 in Pulmonary and Respiratory Medicine, reflecting its significant contributions to the academic community. With a mission to foster the exchange of innovative ideas and encourage rigorous scholarly discourse, Tuberkuloz ve Toraks plays an essential role in addressing pressing health challenges associated with respiratory ailments and remains an invaluable resource for researchers, health professionals, and students dedicated to improving outcomes in thoracic health.
PULMONARY PHARMACOLOGY & THERAPEUTICS
Elevating standards in pulmonary pharmacology and therapy.Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.
Chronic Respiratory Disease
Fostering collaboration in respiratory health advancements.Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.
RESPIRATORY RESEARCH
Bridging Research and Clinical Excellence in Respiratory CareRESPIRATORY RESEARCH is a leading open-access journal published by BMC, dedicated to advancing the field of pulmonary and respiratory medicine. Since its inception in 2000, this journal has provided a vital platform for disseminating high-quality research, covering a broad spectrum of topics from basic science to innovative clinical practices in respiratory health. With an impressive impact factor and a Q1 ranking in the Pulmonary and Respiratory Medicine category, RESPIRATORY RESEARCH is recognized for its significant contribution to the literature, currently positioned at rank #19 out of 155 in the Scopus database, highlighting its relevance and influence within the medical community. The journal’s commitment to open access ensures that all articles are freely available to researchers, professionals, and students, fostering collaboration and knowledge sharing in the field. With its convergence years spanning from 2000 to 2024, RESPIRATORY RESEARCH remains at the forefront of respiratory medicine research, making it an essential resource for all stakeholders in this vital medical domain.
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine
Connecting Researchers and Practitioners in Clinical MedicineClinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine, published by SAGE Publications Ltd, stands as a vital resource in the fields of Cardiology and Pulmonary Medicine, underscored by its Q3 quartile rankings in both areas for 2023. Established in 2007 as an open-access journal, it facilitates the dissemination of cutting-edge research and observations from the international scientific community. With an ISSN of 1179-5484, the journal has garnered recognition for its contributions to clinical medicine, particularly covering topics of circulatory, respiratory, and pulmonary health. The journal not only aims to bridge the gap between research and clinical practice but also to serve as a platform for innovative ideas and collaborations among researchers, healthcare professionals, and trainees. By offering unrestricted access to its articles, Clinical Medicine Insights ensures that vital knowledge reaches a broad audience, ultimately fostering advancements in medical science and patient care.
CHEST
Advancing knowledge in cardiology and critical care.CHEST is a premier journal published by Elsevier, focusing on the vital fields of cardiology, critical care, and pulmonary medicine. Established in 1970, this esteemed journal has continually provided authoritative research, reviews, and clinical studies, catering to a global audience of healthcare professionals, researchers, and students. With an impressive impact factor, CHEST ranks in the top quartile (Q1) across its core categories according to the latest Scopus metrics, securing its position as a leading resource within cardiology (Rank #16), pulmonary (Rank #9), and critical care (Rank #8). Published quarterly, it offers a wealth of knowledge essential for advancing understanding and improving patient outcomes in these critical areas of healthcare. Researchers and practitioners are encouraged to submit their work, contributing to the ongoing discourse that shapes innovative practices and policies in respiratory and cardiovascular health.
Respiratory Investigation
Advancing knowledge in Pulmonary and Respiratory Medicine.Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.
Tuberculosis and Respiratory Diseases
Connecting researchers in the fight against tuberculosis.Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.